体外膜氧合在重型创伤性颅脑损伤中安全吗
该回顾性队列研究利用创伤质量改进计划(2017-2020)数据,纳入18岁及以上、头部简明损伤定级≥3的重型创伤性颅脑损伤患者,比较接受体外膜氧合与未接受者的结局。共识别10,065例患者,其中221例(2.2%)接受体外膜氧合。在134对倾向性匹配样本中,两组死亡率无差异;体外膜氧合组脑血管意外发生率更高(9% vs 1%,p=0.006),呼吸机相关性肺炎发生率更低。64对匹配样本的亚组分析显示,接受抗凝治疗者死亡率更低,但非计划重返手术室更多、机械通气时间和重症监护病房住院时间更长。作者认为体外膜氧合与更高死亡率无关,可作为该人群的潜在干预措施,但抗凝对神经功能结局的影响、合适剂量和时机尚需进一步研究。
要点
- 在134对倾向性匹配的重型颅脑损伤患者中,接受体外膜氧合者与未接受者死亡率无差异。
- 体外膜氧合组脑血管意外发生率高于对照组(9% vs 1%,p=0.006)。
- 体外膜氧合组呼吸机相关性肺炎发生率低于对照组。
- 64对匹配样本亚组分析中,接受抗凝治疗者死亡率更低,但非计划重返手术室更多、机械通气时间和ICU住院时间更长。
- 作者认为体外膜氧合可考虑用于重型颅脑损伤患者,抗凝的神经功能影响、剂量和时机尚需进一步研究。
适用人群与场景
- 创伤质量改进计划(2017-2020)中18岁及以上、头部简明损伤定级≥3的重型创伤性颅脑损伤患者,且住院期间接受体外膜氧合或发生院内心脏骤停或急性呼吸窘迫综合征。
- 排除:到达时无生命体征、院前心脏骤停、不可救治性损伤、到达后48小时内转出、作为转院患者到达后12小时内死亡,以及院内死亡率信息缺失者。
研究设计与关键结果
- 研究类型:回顾性队列研究,使用创伤质量改进计划(2017-2020)数据;纳入10,065例患者,其中221例(2.2%)接受体外膜氧合。
- 在134对倾向性匹配样本中,体外膜氧合组与对照组死亡率无差异。
- 体外膜氧合组脑血管意外发生率高于对照组(9% vs 1%,p=0.006)。
- 体外膜氧合组呼吸机相关性肺炎发生率低于对照组。
- 在64对匹配样本的亚组分析中,接受抗凝治疗者死亡率更低,但非计划重返手术室更多、机械通气时间和重症监护病房住院时间更长。
证据类型、等级与局限
- 证据类型:回顾性队列研究;证据等级:治疗/照护管理,Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,体外膜氧合用于重型创伤性颅脑损伤患者与更高死亡率无关,可考虑作为该人群的潜在干预措施。
- 作者指出,全身抗凝显示死亡率获益,但尚需进一步研究以阐明其对神经功能结局的影响以及抗凝的合适剂量和时机。
- 体外膜氧合组脑血管意外发生率更高(9% vs 1%,p=0.006),呼吸机相关性肺炎发生率更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with severe traumatic brain injury (TBI) are at an increased risk of respiratory failure refractory to traditional therapies. The safety of extracorporeal membrane oxygenation (ECMO) in this population remains unclear. We aimed to examine outcomes following ECMO compared with traditional management in severe TBI patients.
METHODS: We performed a retrospective cohort study using the Trauma Quality Improvement Program (2017-2020). We identified patients 18 years or older with severe TBI (Abbreviated Injury Score head, ≥3) who underwent ECMO or had either in-hospital cardiac or acute respiratory distress syndrome during their hospitalization. The study excluded pPatients who arrived without signs of life, had a prehospital cardiac arrest, had an unsurvivable injury, were transferred out within 48 hours of arrival, or were received as a transfer and died within 12 hours of arrival Patients with missing information regarding in-hospital mortality were also excluded. Outcomes included mortality, in-hospital complications, and intensive care unit length of stay. To account for patient and injury characteristics, we used 1:1 propensity matching. We performed a subgroup analysis among ECMO patients, comparing patients who received anticoagulants with those who did not.
RESULTS: We identified 10,065 patients, of whom 221 (2.2%) underwent ECMO. In the propensity-matched sample of 134 pairs, there was no difference in mortality. Extracorporeal membrane oxygenation was associated with a higher incidence of cerebrovascular accidents (9% vs. 1%, p = 0.006) and a lower incidence of ventilator-associated pneumonia. In the subgroup analysis of 64 matched pairs, patients receiving anticoagulation had lower mortality, higher unplanned return to the operating room, and longer duration of ventilation and intensive care unit length of stay.
CONCLUSION: Extracorporeal membrane oxygenation use in severe TBI patients was not associated with higher mortality and should be considered a potential intervention in this patient population. Systemic anticoagulation showed mortality benefit, but further work is required to elucidate the impact on neurological outcomes, and the appropriate dosing and timing of anticoagulation.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Rafaqat W, Luckoski J, Lagazzi E, et al. Extracorporeal membrane oxygenation in severe traumatic brain injury: Is it safe? J Trauma Acute Care Surg. 2024. PMID: 39238101. doi:10.1097/TA.0000000000004421
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。